An observational study in Cervical Cancer, Endometrial Cancer and Fallopian Tube Cancer, sponsored by Northwestern University. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-28.
Sponsored by Northwestern University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 834 studies in Uterine Cervical Neoplasms with a site in United States — 143 open to participants now, 218 under way, 6 of them phase 3. Uterine Cervical Neoplasms · United States.
Among the 834 studies in Uterine Cervical Neoplasms with a site in United States, this one is the 11th largest by planned enrollment of the 124 observational ones that give a count, is one of 14 that started in 2000, is one of 126 observational ones, reaches primary completion later than 203 of the 217 other live ones, and was the 29th registered.
2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.
Browse Uterine Cervical Neoplasms studies →143 of the 834 studies in Uterine Cervical Neoplasms with a site in United States are open now. Recruiting first, the newest first:
Rutgers, The State University of New Jersey · Sites in United States
Ages 30–65 · Women only · Healthy volunteers
Florida A&M University · Sites in United States
Ages 21–65 · Women only · Healthy volunteers
City of Hope Medical Center · Sites in United States
Ages 18+ · Women only
Mark Bernard · Sites in United States
Ages 18–99
University of Florida · Sites in United States
Ages 25+ · Women only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.
This study: 18 Years to 80 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
834 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 242 · Phase 2 240 · Phase 3 45 · Phase 4 9
First in 1992; this study’s year is marked. 14 started in 2000.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 6,000 is above the median of 220 across 530 observational studies indexed under Uterine Cervical Neoplasms.
Median enrollment 71 across the 678 interventional studies, 138 across the 124 observational. Of the 570 that completed or were terminated, 193 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
213 of 834 have an industry lead sponsor. The 10 most frequent:
Northwestern University is the lead sponsor of 1,424 studies on the registry; 199 are open to participants now.
Of its 105 completed or terminated interventional studies of FDA-regulated products, 78 (74%) have results posted.
Northwestern University has 6 studies filed under Uterine Cervical Neoplasms — fewer than ten, so there is no comparison to draw.
84 of the studies in Uterine Cervical Neoplasms with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06079671Phase 3AstraZenecaStudy of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical) | 2027-11-26 |
| NCT02285192Memorial Sloan Kettering Cancer CenterPositron Lymphography Via Intracervical 18F-FDG Injection for Pre-surgical Lymphatic Mapping in Stage IB1 Cervical Cancer and High-grade Endometrial Cancer | 2026-11 |
| NCT05758688Abramson Cancer Center at Penn MedicinePROton Therapy for Post Surgical Treatment of GYNecologic Cancer | 2026-11 |
| NCT07574190University of South DakotaA Mobile Web App Intervention to Promote Cervical Cancer Screening | 2026-11 |
| NCT00579163Memorial Sloan Kettering Cancer CenterAscertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers | 2026-12 |
Add all 84 to your calendar (.ics) → With an account.
Among the 834 studies in Uterine Cervical Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
RATIONALE: To improve strategies for detection and prevention of early-stage disease.
PURPOSE: This research study is collecting specimens and data to develop better methods for early detection and prevention of ovarian cancer among the high risk population and those who have the disease.
OBJECTIVES:
OUTLINE: Subjects undergo periodic specimen and data collection for research studies, including molecular, biochemical, functional, and genetic marker studies. Participants may have samples of blood, tissue, or body fluids (such as ascites, pleural fluid or urine), or any combination of the aforementioned samples obtained to develop tumor markers to detect early stage or recurrent ovarian cancer.
The results from the biomarker research studies will not be reported to the patient or the physician. In the future, if any of the experimental tumor markers are found to be effective in detecting early stage ovarian cancer, and the patient's result is abnormal, the patient and physician will be notified.
Subjects may be asked to complete a combination of questionnaires designed to evaluate psychological functioning among women enrolled in a comprehensive ovarian cancer early detection program who are at increased risk for developing disease as compared to women currently diagnosed with ovarian cancer.
Women at high risk of ovarian cancer due to family or personal medical history, or a gynecologic abnormality.
DISEASE CHARACTERISTICS:
Meets one of the following criteria:
Considered to be at increased risk for developing ovarian cancer, as defined by one of the following:
Undergoing surgery for a gynecologic condition, including any of the following:
PATIENT CHARACTERISTICS:
Age
Women who are at increased risk of ovarian cancer based on family or personal medical history who are participating in the Northwestern Ovarian Cancer Early Detection and Prevention Program clinic.
Other: Ca-125 · Other: screening questionnaire administration · Procedure: Surgery
Women who are planning to undergo surgery for their gynecological condition
Healthy subjects with no history of cancer and at general risk.
Subject's blood collected at their follow-up blood draw will be assessed for biomarkers that could lead to a panel for detecting early stage ovarian cancer.
Questionnaires designed to assess quality of life for women at increased risk of ovarian cancer will be administered to the subjects. Clinical data will also be collected.
Also known as: Questionnaire
Subjects will be assessed for high risk factors.
Also known as: BSO, fallopian tubes, TAH, hysterectomy, bilateral salpingectomy, STIC
The development of ultrasound and serum tumor markers for the detection and management of ovarian cancer and other
To identify markers to allow for presymptomatic testing for ovarian and other gynecological malignancies
Time frame: 1 year
new prevention approaches and therapies for risk assessment
To identify new prevention approaches and therapies by researching and reviewing the risk of developing disease.
Time frame: 1 year
The develop of measures to improve the quality of life for women at increased risk for developing the disease and for women diagnosed with ovarian cancer
To identify the measurements to improve the quality of life for women at increased risk for developing the disease
Time frame: 1 year
Started Mar 2000 (actual). Primary completion is estimated for Dec 2030, 369 months after the start.
Of 190 non-industry observational studies under Uterine Cervical Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 158. This study's planned 369 months is above that.
Counting every sponsor, half of 214 studies reached it within 58 months; a quarter within 28 and three quarters within 158.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.